Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Transactivation of the estrogen receptor promoter by BRCA1.

Archey WB, Arrick BA.

Cancer Cell Int. 2017 Mar 2;17:33. doi: 10.1186/s12935-017-0401-2. eCollection 2017.

2.

BRCA1 splice variants exhibit overlapping and distinct transcriptional transactivation activities.

McEachern KA, Archey WB, Douville K, Arrick BA.

J Cell Biochem. 2003 May 1;89(1):120-32.

PMID:
12682913
3.

Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers.

Archey WB, McEachern KA, Robson M, Offit K, Vaziri SA, Casey G, Borg A, Arrick BA.

Oncogene. 2002 Oct 10;21(46):7034-41.

4.

Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.

Tobin SW, Douville K, Benbow U, Brinckerhoff CE, Memoli VA, Arrick BA.

Oncogene. 2002 Jan 3;21(1):108-18.

5.

Inhibition of transforming growth factor beta signaling in MCF-7 cells results in resistance to tumor necrosis factor alpha: a role for Bcl-2.

Tobin SW, Brown MK, Douville K, Payne DC, Eastman A, Arrick BA.

Cell Growth Differ. 2001 Feb;12(2):109-17.

7.

RESPONSE: more about: multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations

Brown DL, Cole BF, Arrick BA.

J Natl Cancer Inst. 1999 Aug 18;91(16):1422. No abstract available.

PMID:
10451452
8.
9.

Re: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.

Brown DL, Cole BF, Arrick BA.

J Natl Cancer Inst. 1999 Jan 6;91(1):90-1. No abstract available.

PMID:
9890178
10.
11.

Therapeutic implications of the TGF-beta system.

Arrick BA.

J Mammary Gland Biol Neoplasia. 1996 Oct;1(4):391-7. Review.

PMID:
10887513
12.
13.

Association of heterogeneous nuclear ribonucleoprotein A1 and C proteins with reiterated AUUUA sequences.

Hamilton BJ, Nagy E, Malter JS, Arrick BA, Rigby WF.

J Biol Chem. 1993 Apr 25;268(12):8881-7.

14.

Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer.

Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA.

Cancer Res. 1992 Dec 15;52(24):6949-52.

15.
16.

Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta.

Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA, Clarke-Pearson DL, Bast RC Jr.

Am J Obstet Gynecol. 1992 Feb;166(2):676-84.

PMID:
1536252
17.

Growth regulation by transforming growth factor-beta.

Arrick BA, Derynck R.

Cancer Treat Res. 1992;63:255-64. Review. No abstract available.

PMID:
1363360
18.

Inhibition of translation of transforming growth factor-beta 3 mRNA by its 5' untranslated region.

Arrick BA, Lee AL, Grendell RL, Derynck R.

Mol Cell Biol. 1991 Sep;11(9):4306-13.

19.
20.
22.

Glutathione metabolism as a determinant of therapeutic efficacy: a review.

Arrick BA, Nathan CF.

Cancer Res. 1984 Oct;44(10):4224-32. Review.

23.
24.

The cutaneous infiltrates of leprosy: cellular characteristics and the predominant T-cell phenotypes.

Van Voorhis WC, Kaplan G, Sarno EN, Horwitz MA, Steinman RM, Levis WR, Nogueira N, Hair LS, Gattass CR, Arrick BA, Cohn ZA.

N Engl J Med. 1982 Dec 23;307(26):1593-7.

PMID:
6216407
25.

Glutathione depletion sensitizes tumor cells to oxidative cytolysis.

Arrick BA, Nathan CF, Griffith OW, Cohn ZA.

J Biol Chem. 1982 Feb 10;257(3):1231-7. No abstract available.

26.

Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis.

Nathan CF, Arrick BA, Murray HW, DeSantis NM, Cohn ZA.

J Exp Med. 1981 Apr 1;153(4):766-82.

27.

Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis.

Arrick BA, Griffith OW, Cerami A.

J Exp Med. 1981 Mar 1;153(3):720-5.

Supplemental Content

Loading ...
Support Center